January 9, 2023
Life Sciences
  • The Food and Drug Administration on Friday approved Leqembi – a new Alzheimer’s disease treatment that moderately slows cognitive decline in people with early-stage disease. Eisai Co., the Japanese pharmaceutical company that developed the drug with Biogen Inc., said it will price the drug at $26,500 annually for the average eligible patient. While the price is below what Biogen set for its previous Alzheimer’s drug Aduhelm, there may still be pushback for the treatment being too expensive. (Articles here, here, here, here, and here)